HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Recommendation of “Hold” by Analysts

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has received a consensus recommendation of “Hold” from the five ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $20.8750.

A number of equities analysts have commented on the stock. Morgan Stanley cut shares of HUTCHMED from an “equal weight” rating to an “underweight” rating and dropped their price objective for the stock from $18.00 to $13.75 in a research note on Monday, September 22nd. Wall Street Zen raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a research note on Wednesday, October 8th.

Institutional Trading of HUTCHMED

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Personalized Indexing Management LLC boosted its stake in HUTCHMED by 23.2% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock worth $233,000 after buying an additional 2,916 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of HUTCHMED by 17.3% during the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after purchasing an additional 3,035 shares during the period. Dimensional Fund Advisors LP grew its holdings in HUTCHMED by 34.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after purchasing an additional 5,538 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in HUTCHMED by 19.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock worth $377,000 after purchasing an additional 4,116 shares during the period. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Stock Performance

Shares of HCM opened at $14.72 on Friday. The company’s fifty day moving average is $14.17 and its 200 day moving average is $15.43. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.51 and a current ratio of 4.65. HUTCHMED has a fifty-two week low of $11.51 and a fifty-two week high of $19.50.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.